Immunocore Holdings plc ADR (IMCR) concluded trading on Wednesday at a closing price of $31.70, with 0.44 million shares of worth about $14.1 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 9.65% during that period and on June 18, 2025 the price saw a loss of about -2.04%. Currently the company’s common shares owned by public are about 50.18M shares, out of which, 48.62M shares are available for trading.
Stock saw a price change of -10.85% in past 5 days and over the past one month there was a price change of 2.26%. Year-to-date (YTD), IMCR shares are showing a performance of 7.46% which decreased to -17.58% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $23.15 but also hit the highest price of $41.54 during that period. The average intraday trading volume for Immunocore Holdings plc ADR shares is 410.92K. The stock is currently trading -8.69% below its 20-day simple moving average (SMA20), while that difference is up 1.32% for SMA50 and it goes to 1.84% higher than SMA200.
Immunocore Holdings plc ADR (NASDAQ: IMCR) currently have 50.18M outstanding shares and institutions hold larger chunk of about 91.54% of that.
The stock has a current market capitalization of $1.59B and its 3Y-monthly beta is at 0.83. It has posted earnings per share of -$0.44 in the same period. It has Quick Ratio of 6.31 while making debt-to-equity ratio of 1.15. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IMCR, volatility over the week remained 1.60% while standing at 3.59% over the month.
Stock’s fiscal year EPS is expected to rise by 23.65% while it is estimated to decrease by -63.23% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Deutsche Bank on May 27, 2025 offering a Buy rating for the stock and assigned a target price of $65 to it. Coverage by Morgan Stanley stated Immunocore Holdings plc ADR (IMCR) stock as an Equal-weight in their note to investors on December 13, 2024, suggesting a price target of $35 for the stock. On November 11, 2024, Mizuho Downgrade their recommendations, while on October 24, 2024, UBS Initiated their ratings for the stock with a price target of $24. Stock get a Neutral rating from Guggenheim on October 07, 2024.
